- Category
- Medium (2024-25)
- Udyam number
- UDYAM-GJ-24-0003717

About Aristo Bio-Tech and Lifescience Limited
Data last updated:
Aristo Bio-Tech and Lifescience Limited is a public limited company based in Vadodara, Gujarat, India. It operates in the chemical products segment of the chemicals sector. It was incorporated on 17 March 2005 and has been in existence for over 21 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L01100GJ2005PLC127397. Its GSTIN is 24AAFCA1552P1ZL (Gujarat). The company holds 6 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on NSE: ARISTO.
The company has an authorised share capital of ₹8 Cr and a paid-up capital of ₹6.81 Cr. It was formerly known as Aristo Bio-Tech and Lifescience Private Limited. It is led by directors including Narendra Singh Barhat (Managing Director) and Ketankumar Harkantbhai Joshi (Whole-Time Director).
Its last annual general meeting (AGM) was held on 08 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at E – 24 25 26 G.I.D.C. Manjusar Ta. Savli, Vadodara, Gujarat, India – 391775.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹363.72 Cr, a growth of 14.3% compared to the previous year. For the same year it recorded a net profit of ₹7.19 Cr (net margin 2%) and EBITDA of ₹16.05 Cr (EBITDA margin 4.4%). The net worth stands at ₹44.11 Cr (up 18.2% YoY). Total assets are valued at ₹79.5 Cr (up 34.3% YoY).
The company has about 67 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Aristo Biotech. As per MCA filings, the company has open charges of ₹73.42 Cr and satisfied charges of ₹9.61 Cr on record. Court records list 11 cases involving the company, including 8 filed by the company and 3 filed against it; 1 case is pending. The company has 4 deals on record (3 funding rounds, 1 ipo), with disclosed funding of ₹1.19 Cr; the latest was in January 2023. Its 6 peer companies in the Agriculture industry (Pesticides), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 2 smaller; the largest is Iffco-Mc Crop Science Private Limited with revenue of ₹364.68 Cr. The company has 16 MSME Form 1 returns on record between 2017 and 2022, listing 854 overdue payments to 60 micro and small suppliers.
Aristo Bio-Tech and Lifescience Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-24-0003717). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aristobiotech.com.
Company details
CIN history
Aristo Bio-Tech and Lifescience has 3 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L01100GJ2005PLC127397, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L01100GJ2005PLC127397 | Current |
| U01100GJ2005PLC127397 | Previous |
| U01100MH2005PTC152037 | Previous |
| U01100MH2005PLC152037 | Previous |
Recognitions & Rankings of Aristo Bio-Tech and Lifescience
Contact details
Aristo Bio-Tech and Lifescience Limited's registered office is in Vadodara, Gujarat. Its website is aristobiotech.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressE – 24 25 26 G.I.D.C. Manjusar Ta. Savli, Vadodara, Gujarat, India – 391775
- IndustryChemicals, Chemical Products, Medicinal Chemical & Botanical Products, Pharmaceuticals
To see the full contact details of Aristo Bio-Tech and Lifescience Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Aristo Bio-Tech and Lifescience operates one associated brand: Aristo Biotech. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Audio news content is provided to radio stations for broadcast. | aristobiotech.com |
Business activity
The main business activity of Aristo Bio-Tech and Lifescience is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Aristo Bio-Tech and Lifescience Limited, buy the company report.
Financials of Aristo Bio-Tech and Lifescience Limited
FY 2025-26 filings availableAristo Bio-Tech and Lifescience Limited reported revenue of ₹363.72 Cr (up 14.3% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 364 | 318 | 245 | 218 | 166 | 167 | 201 |
| Revenue growth | +14.3% | +29.8% | +12.5% | +31.3% | -0.7% | -16.9% | - |
| EBITDA | 16.05 | 9.27 | 8.49 | 8.70 | 5.47 | 4.35 | 4.50 |
| EBITDA margin | +4.4% | +2.9% | +3.5% | +4.0% | +3.3% | +2.6% | +2.2% |
| Profit before tax | 9.70 | 5.46 | 5.41 | 4.74 | 2.05 | 1.50 | 1.39 |
| Net profit | 7.19 | 4.01 | 3.90 | 3.56 | 1.47 | 1.08 | 1.00 |
| Net profit margin | +2.0% | +1.3% | +1.6% | +1.6% | +0.9% | +0.7% | +0.5% |
| EPS (₹) | 10.55 | 5.97 | 5.72 | 5.23 | 2.93 | 2.15 | 2.02 |
| Balance sheet | |||||||
| Total assets | 79.50 | 59.19 | 54.48 | 52.67 | 40.33 | 35.63 | 32.01 |
| Net worth | 44.11 | 37.33 | 33.61 | 30.16 | 14.85 | 13.39 | 12.31 |
| Total debt | 35.40 | 21.85 | 20.87 | 22.49 | 25.48 | 22.25 | 19.71 |
| Cash & bank | 2.63 | 1.12 | 0.64 | 1.85 | 0.42 | 0.11 | 0.53 |
| Net working capital | 54.46 | 34.41 | 32.34 | 35.94 | 25.97 | 23.32 | 20.87 |
| Cash flow | |||||||
| Cash from operations | 8.85 | 10.02 | 7.60 | (2.78) | 6.82 | 2.28 | 1.41 |
| Cash from investing | (2.97) | (5.15) | (6.61) | (3.75) | (3.19) | (1.98) | (2.19) |
| Cash from financing | (4.37) | (4.39) | (2.21) | 7.97 | (3.33) | (0.72) | 0.87 |
Financial Statements
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 364 | 318 | 245 | 218 | 166 | 167 | 201 |
| Revenue growth | +14.3% | +29.8% | +12.5% | +31.3% | -0.7% | -16.9% | - |
| Other income | 0.46 | 0.45 | 0.18 | 0.33 | 0.04 | 0.01 | 0.01 |
| Total expenses | 348 | 309 | 237 | 209 | 161 | 163 | 197 |
| Employee cost | 0.00 | 3.08 | 2.65 | 4.74 | 4.29 | 2.52 | 2.72 |
| EBITDA | 16.05 | 9.27 | 8.49 | 8.70 | 5.47 | 4.35 | 4.50 |
| EBITDA margin | +4.4% | +2.9% | +3.5% | +4.0% | +3.3% | +2.6% | +2.2% |
| Depreciation | 2.92 | 2.60 | 1.57 | 1.54 | 1.10 | 0.75 | 0.52 |
| Interest | 3.89 | 1.66 | 1.69 | 2.75 | 2.36 | 2.11 | 2.60 |
| Profit before tax | 9.70 | 5.46 | 5.41 | 4.74 | 2.05 | 1.50 | 1.39 |
| Tax | 2.51 | 1.40 | 1.51 | 1.18 | 0.57 | 0.42 | 0.39 |
| Net profit | 7.19 | 4.01 | 3.90 | 3.56 | 1.47 | 1.08 | 1.00 |
| Net profit margin | +2.0% | +1.3% | +1.6% | +1.6% | +0.9% | +0.7% | +0.5% |
| EPS (₹) | 10.55 | 5.97 | 5.72 | 5.23 | 2.93 | 2.15 | 2.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 6.81 | 6.81 | 6.81 | 6.81 | 5.00 | 5.00 | 5.00 |
| Reserves & surplus | 37.30 | 30.52 | 26.80 | 23.35 | 9.85 | 8.39 | 7.31 |
| Shareholders' funds (net worth) | 44.11 | 37.33 | 33.61 | 30.16 | 14.85 | 13.39 | 12.31 |
| Secured loans | 32.07 | 18.06 | 16.75 | 18.83 | 22.04 | 18.61 | 13.87 |
| Unsecured loans | 3.33 | 3.79 | 4.12 | 3.66 | 3.44 | 3.64 | 5.84 |
| Total debt | 35.40 | 21.85 | 20.87 | 22.49 | 25.48 | 22.25 | 19.71 |
| Total liabilities | 79.50 | 59.19 | 54.48 | 52.67 | 40.33 | 35.63 | 32.01 |
| Assets | |||||||
| Gross block | 37.37 | 34.76 | 30.20 | 22.74 | 19.94 | 16.88 | 12.08 |
| Net block | 23.63 | 23.95 | 21.69 | 15.62 | 14.36 | 12.31 | 8.26 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 1.10 | 0.10 | 0.00 | 2.82 |
| Investments | 0.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 63.21 | 47.37 | 40.19 | 30.78 | 24.36 | 31.95 | 24.32 |
| Sundry debtors | 54.73 | 56.18 | 57.47 | 44.57 | 33.20 | 32.77 | 48.31 |
| Cash & bank balances | 2.63 | 1.12 | 0.64 | 1.85 | 0.42 | 0.11 | 0.53 |
| Loans & advances | 9.59 | 11.10 | 6.73 | 5.90 | 4.56 | 4.28 | 3.55 |
| Total current assets | 130 | 116 | 105 | 83.10 | 62.54 | 69.11 | 76.71 |
| Total current liabilities | 75.70 | 81.36 | 72.69 | 47.16 | 36.57 | 45.79 | 55.84 |
| Net working capital | 54.46 | 34.41 | 32.34 | 35.94 | 25.97 | 23.32 | 20.87 |
| Total assets | 79.50 | 59.19 | 54.48 | 52.67 | 40.33 | 35.63 | 32.01 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 1.12 | 0.64 | 1.85 | 0.42 | 0.11 | 0.53 | 0.44 |
| Net cash from operating activities | 8.85 | 10.02 | 7.60 | (2.78) | 6.82 | 2.28 | 1.41 |
| Net cash from investing activities | (2.97) | (5.15) | (6.61) | (3.75) | (3.19) | (1.98) | (2.19) |
| Net cash from financing activities | (4.37) | (4.39) | (2.21) | 7.97 | (3.33) | (0.72) | 0.87 |
| Net change in cash | 1.51 | 0.48 | (1.22) | 1.44 | 0.31 | (0.41) | 0.09 |
| Closing cash | 2.63 | 1.12 | 0.64 | 1.85 | 0.42 | 0.11 | 0.53 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +14.3% | +29.8% | +12.5% | +31.3% | -0.7% | -16.9% | - |
| EBITDA growth | +73.1% | +9.2% | -2.4% | +59.1% | +25.8% | -3.3% | - |
| PBT growth | +77.7% | +0.9% | +14.1% | +131.2% | +36.7% | +7.9% | -66.1% |
| Net income growth | +79.3% | +2.8% | +9.6% | +142.2% | +36.1% | +8.0% | - |
| Revenue CAGR (3Y) | +18.6% | +24.2% | +13.6% | +2.7% | -6.3% | -14.9% | +7.9% |
| EBITDA CAGR (3Y) | +22.7% | +19.2% | +25.0% | +24.6% | -6.8% | -15.9% | +21.0% |
| Profitability & leverage | |||||||
| Net income margin | +2.0% | +1.3% | +1.6% | +1.6% | +0.9% | +0.7% | +0.5% |
| Return on capital employed | - | +12.5% | +13.3% | +16.1% | +11.6% | +10.7% | +13.9% |
| Return on net worth | - | +11.5% | +12.2% | +15.8% | +10.3% | +8.4% | +8.6% |
| Debt / equity | - | 0.60 | 0.68 | 1.07 | 1.69 | 1.63 | 1.45 |
| Long-term debt / equity | - | 0.25 | 0.32 | 0.47 | 0.82 | 0.88 | 0.76 |
| Interest cover | 29.63 | 24.89 | 24.42 | 38.41 | 54.00 | 58.61 | 65.33 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 9.79 | 9.26 | 10.21 | 10.38 | 13.54 | 20.22 |
| Inventory turnover | - | 7.27 | 6.91 | 7.90 | 6.79 | 6.97 | 8.22 |
| Debtors turnover | - | 5.60 | 4.80 | 5.60 | 5.80 | 4.84 | 5.20 |
| EPS (₹) | 10.55 | 5.97 | 5.72 | 5.23 | 2.93 | 2.15 | 2.02 |
| Dividend per share (₹) | 0.60 | 0.50 | 0.40 | 0.25 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 54.84 | 49.37 | 44.30 | 29.71 | 26.79 | 24.63 |
To see the full year-wise statements and ratios of Aristo Bio-Tech and Lifescience Limited, buy the company report.
Board of directors of Aristo Bio-Tech and Lifescience Limited
Aristo Bio-Tech and Lifescience has 6 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Raghavender Mateti | Director | 10 Sep 2018 | 8 Years 2 Months | Current |
| Laxman Singh Rathore | Director | 20 Mar 2022 | 4 Years 7 Months | Current |
| Kusum Narendra Singh Barhat Also directs: Barhatji Mewar (Paaner) Foundation | Director | 17 Mar 2005 | 21 Years 8 Months | Current |
| Narendra Singh Barhat Also directs: Barhatji Mewar (Paaner) Foundation, Indus Finechem LLP | Managing Director | 17 Mar 2005 | 21 Years 8 Months | Current |
| Ketankumar Harkantbhai Joshi Also directs: Indus Finechem LLP | Whole-Time Director | 27 Aug 2018 | 8 Years 2 Months | Current |
| Rashmi Kamlesh Otavani | Director | 20 Mar 2022 | 4 Years 7 Months | Current |
Peer comparison
Aristo Bio-Tech and Lifescience Limited is compared with the 6 companies closest to it by revenue in the Agriculture industry (Pesticides), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Iffco-Mc Crop Science Private Limited | ₹364.68 Cr (FY 2025) | 7.0% | New Delhi, Delhi, India | |||
| Aristo Bio-Tech and Lifescience Limitedthis company | ₹363.72 Cr (FY 2026) | ₹7.19 Cr | 2% | 14.3% | 67 | Vadodara, Gujarat, India |
| Spectrum Ethers Private Limited | ₹354.8 Cr (FY 2025) | 16.0% | Nashik, Maharashtra, India | |||
| Ramcides Cropscience Private Limited | ₹346.13 Cr (FY 2025) | 14.0% | Chennai, Tamil Nadu, India | |||
| Sumil Chemical Industries Private Limited | ₹325.3 Cr (FY 2025) | -1.0% | Mumbai, Maharashtra, India | |||
| Shivalik Crop Sciences Private Limited | ₹317.93 Cr (FY 2025) | 12.0% | Chandigarh, India | |||
| Agrico Organics Limited | ₹300.46 Cr (FY 2025) | 12.0% | Delhi, India |
To see the full peer comparison of Aristo Bio-Tech and Lifescience Limited, buy the company report.
Auditor
Aristo Bio-Tech and Lifescience Limited is audited by PRAKASH CHANDRA JAIN & CO. for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| PRAKASH CHANDRA JAIN & CO. | FY 2024 | 002438C |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 73.40%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 26.60%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 73.40% | 73.40% | 73.40% | 73.40% |
| Public | 26.60% | 26.60% | 26.60% | 26.60% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 08 Apr 2026 | 101283930 | Others | ₹96.68 Lakh | Open | |
| 30 Mar 2026 | 101282317 | Sidbi | ₹75 Lakh | Open | |
| 31 Dec 2025 | 101207130 | Sidbi | ₹1 Cr | Open | |
| 28 Aug 2025 | 101151870 | Standard Chartered Bank | ₹1 Cr | Open | |
| 18 Feb 2025 | 101054045 | Sidbi | ₹2.74 Cr | Open |
To see the full charge records of Aristo Bio-Tech and Lifescience Limited, buy the company report.
Total charge records: 14 View all charges
Deals & funding
Aristo Bio-Tech and Lifescience Limited has 4 deals on record (3 funding rounds, 1 ipo), with disclosed funding of ₹1.19 Cr; the latest was in January 2023.
Deals on record (4 of 4)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jan 2023 | IPO | ₹13.05 Cr | Investors: IPO Shareholders - Aristo Bio-Tech And Lifescience Limited |
| Mar 2012 | Funding round | ₹59.9 Lakh | Investors: 4 individuals |
| Mar 2012 | Funding round | ₹10 Lakh | Investors: an individual |
| Mar 2007 | Funding round | ₹49 Lakh | Investors: Narendra Singh Barhat HUF, 3 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Aristo Bio-Tech and Lifescience Limited has 11 court cases on record: 8 filed by Aristo Bio-Tech and Lifescience, 3 filed against it. 1 case is pending and 10 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 8 | 2 | 1 |
| High courts | 3 | 1 | 0 |
Cases on record (5 of 11)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Ahmedabad, Gujarat | Criminal complaint | Filed against the company by Kalpesh Chandrakant Patel Authorised Person of Dharmaj Crop Guard Ltd. | Disposed |
| District court, Vadodara, Gujarat | Commercial matter | Filed against the company by an individual | Pending |
| District court, Ambala, Haryana | Criminal miscellaneous application | Filed by the company against an individual | Disposed |
| District court, Kurukshetra, Haryana | Criminal miscellaneous application | Filed by the company against an individual | Disposed |
| District court, Rewari, Haryana | Criminal miscellaneous application | Filed by the company against individuals | Disposed |
To see the full case history of Aristo Bio-Tech and Lifescience Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Aristo Bio-Tech and Lifescience Limited was last rated by Crisil on 27 Oct 2020.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 27 Oct 2020 |
To see the full credit ratings and regulatory alerts of Aristo Bio-Tech and Lifescience Limited, buy the company report.
MSME payment delays
Aristo Bio-Tech and Lifescience Limited has 16 MSME Form 1 returns on record between 2017 and 2022, listing 854 overdue payments to 60 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 60)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Sanjay Chemicals (India) Private Limited | |||
| Anshikha Polysurf Ltd | |||
| Supreme India Cargo | |||
| Amish Crop Sciences Private Limited | |||
| Unitop Chemicals Private Limited |
To see the full MSME payment records of Aristo Bio-Tech and Lifescience Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Aristo Bio-Tech and Lifescience Limited has a workforce of 67 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 67 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of Aristo Bio-Tech and Lifescience Limited, buy the company report.
GST
Aristo Bio-Tech and Lifescience has 6 GST registrations: 1 active and 5 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAFCA1552P1ZL | Gujarat | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Aristo Bio-Tech and Lifescience Limited, buy the company report.
Recent activity
Aristo Bio-Tech and Lifescience Limited has 14 board changes on record since 2005: 10 appointments and 4 cessations. The latest: Ayushi Aditya Deora ceased to be Company Secretary on 29 May 2025.
26 earlier events are in the company report.
News
Frequently asked questions
Aristo Bio-Tech and Lifescience is an active public limited company based in Vadodara, Gujarat, India. The company works in chemical products, within the chemicals industry. It was incorporated on 17 March 2005 (21+ years old) and is registered under CIN L01100GJ2005PLC127397. Listed on NSE: ARISTO.
Aristo Bio-Tech and Lifescience reported revenue of ₹363.72 Cr for FY 2025-26 (up 14.3% YoY) based on standalone financials.
Aristo Bio-Tech and Lifescience has 6 current directors:
- Narendra Singh Barhat - Managing Director
- Ketankumar Harkantbhai Joshi - Whole-Time Director
- Raghavender Mateti - Director
- Laxman Singh Rathore - Director
- Kusum Narendra Singh Barhat - Director
- Rashmi Kamlesh Otavani - Director
The latest financial statements of Aristo Bio-Tech and Lifescience on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 08 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Aristo Bio-Tech and Lifescience is 24AAFCA1552P1ZL, registered in Gujarat. The company has 6 GST registrations in all, of which 1 is active and 5 are cancelled or inactive.
The CIN (Corporate Identification Number) of Aristo Bio-Tech and Lifescience is L01100GJ2005PLC127397. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Aristo Bio-Tech and Lifescience is a listed company as per MCA records. Its shares are listed on NSE (symbol: ARISTO).
Aristo Bio-Tech and Lifescience has 11 court cases on record: 8 filed by the company and 3 filed against it. 1 is pending. Most are in the district courts.
Aristo Bio-Tech and Lifescience was incorporated on 17 March 2005, making it 21+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Aristo Bio-Tech and Lifescience has 4 deals on record (3 funding rounds, 1 ipo), with disclosed funding of ₹1.19 Cr; the latest was in January 2023.
The peers of Aristo Bio-Tech and Lifescience by revenue are Iffco-Mc Crop Science Private Limited, Spectrum Ethers Private Limited, Ramcides Cropscience Private Limited, Sumil Chemical Industries Private Limited, Shivalik Crop Sciences Private Limited and 1 more, all in the Agriculture industry (Pesticides), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Ayushi Aditya Deora ceased to be Company Secretary on 29 May 2025. Ayushi Aditya Deora was appointed as Company Secretary on 19 Mar 2024. Dipakkumar Harkant Joshi ceased to be Director on 08 Nov 2023. Aristo Bio-Tech and Lifescience has 14 board changes on record in total.

